Loading clinical trials...

A Study of ProQuad™ in Healthy Children in Korea (V221-023) | Clinical Trials | Clareo Health

TERMINATEDPHASE3

A Study of ProQuad™ in Healthy Children in Korea (V221-023)

A Multicenter, Randomized, Open-Label Study to Compare the Immunogenicity, Safety, and Tolerability of Measles, Mumps, Rubella, and Varicella of Combination Vaccine ProQuad With Concomitant Administration of M-M-R II and VARIVAX in Healthy Korean Children

NCT00839917•Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

This study will compare ProQuad™ and concomitant administration of M-M-R™ II and Varivax™ with respect to immunogenicity, safety and tolerability. The primary hypothesis to be tested is that the antibody response rates to measles, mumps, rubella, and varicella 6 weeks after vaccination with ProQuad™ will be non-inferior to the antibody response rates after vaccination with concomitant M-M-R™ II and Varivax™.

Eligibility

Age

1 - 1 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Subject is in good health
•Subject has a negative clinical history for measles, mumps, rubella, varicella and zoster

Exclusion Criteria

•Subject has previously received measles, mumps, rubella and/or varicella vaccine, either alone or in any combination
•Subject has any congenital or acquired immune deficiency, neoplastic disease or depressed immunity
•Subject has a history of seizure disorder
•Subject had exposure to measles, mumps, rubella, varicella and/or zoster in the last 4 weeks
•Subject has received an inactivated vaccine within the past 14 days
•Subject has received a live vaccine within the past 30 days
•Subject has received immune globulin within the past 5 months
•Subject has a recent history of fever (within the last 72 hours)

Key Dates

Start Date

February 1, 2008

Primary Completion Date

May 1, 2008

Completion Date

May 1, 2008

Last Updated

April 12, 2017

Enrollment

ACTUAL participants

Conditions

MeaslesMumpsRubellaVaricella

Interventions

Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™)

BIOLOGICAL

M-M-R™ II and Varivax™

BIOLOGICAL

Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections

NCT07112846

ExanthemaDengue Fever+3 more

View study

COMPLETEDPHASE4

Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children

NCT03460002

Measles VaccinationOral Polio Vaccine+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 12, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of ProQuad™ in Healthy Children in Korea (V221-023)

Inclusion Criteria

Exclusion Criteria

Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections

Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children

Co-administration Study of OCV, TCV and MR

Participant Centered Active Surveillance for Adverse Event Following Measles Immunization in Gedeo Zone, Ethiopia, 2022. A Multi-center Open-label Randomized Control Trial

Measles, Mumps, and Rubella (MMR) Immunity in College Students

Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants